Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10088039 | 1.00 | PPM1B (0.47) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL1246430 | 1.00 | PPM1B (0.47) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL6900672 | 1.00 | PPM1B (0.47) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL16349313 | 0.97 | PPM1B (0.46) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL1296897 | 0.92 | ALDH1A1 (0.48) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL2705849 | 0.92 | ALDH1A1 (0.48) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL2705851 | 0.92 | ALDH1A1 (0.48) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL12943060 | 0.92 | ALDH1A1 (0.48) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL8914013 | 0.92 | ALDH1A1 (0.48) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL12988317 | 0.91 | PPM1B (0.50) | PPM1BPTPN1PPP1CCMAPTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328120-B2 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-03 | — | — | US | disclosed |
| US-9328120-B2 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-03 | — | — | US | disclosed |
| US-20150025088-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-20150025088-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-8912201-B2 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912201-B2 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20130040971-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130040971-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20120202829-A1 | 6-Cycloalkyl-pyrazolopyrimidinones for the Treatment of CNS Disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202829-A1 | 6-Cycloalkyl-pyrazolopyrimidinones for the Treatment of CNS Disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-09 | — | — | US | disclosed |
| US-20110212960-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212960-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| WO-2011018495-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040971-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | PDE9A, PDE7A, PDE2A | PPM1B 149/4885PTPN1 1706/4885PPP1CC 1387/4885 |
| US-20120202829-A1 | 6-Cycloalkyl-pyrazolopyrimidinones for the Treatment of CNS Disorders | PDE9A, PDE7A, PDE2A | PPM1B 122/4885PTPN1 1668/4885PPP1CC 1603/4885 |
| US-20110212960-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER | BDNF, PSEN1, CHRNA5 | PPM1B 1020/4885PTPN1 4170/4885PPP1CC 1126/4885 |
| US-20150025088-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | PDE9A, PDE7A, PDE2A | PPM1B 122/4885PTPN1 1668/4885PPP1CC 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.